Zosano Pharma Corporation (ZSAN)

Trade ZSAN now with
6/13/2020 9:21:43 AM Zosano Pharma Presents New Post-hoc Efficacy Analyses Of Qtrypta For The Acute Treatment Of Migraine
3/5/2020 8:17:04 AM Zosano Pharma Plans 11 Mln Direct Offering
2/12/2020 8:25:15 AM Zosano Pharma Reports Pricing Of $8.0 Mln Public Offering Of Common Stock And Warrants
12/23/2019 8:10:31 AM Zosano Pharma Submits 505(b)(2) NDA For Qtrypta To FDA
9/18/2019 8:31:55 AM Zosano Pharma Names Dushyant Pathak As SVP Of Business Development
7/15/2019 6:04:37 AM Zosano Presents Migraine-ACT Scores For Qtrypta Therapy Used Over 6-12 Months
1/16/2019 8:34:20 AM Zosano Appoints Linda Grais To Board
10/16/2018 8:31:41 AM Zosano Pharma Appoints Greg Kitchener CFO
10/3/2018 8:35:25 AM Zosano Pharma Announces Manufacturing And Supply Agreement For M207
9/26/2018 8:31:25 AM Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
9/6/2018 8:38:00 AM Zosano Pharma To Present Phase 3 Safety Study Update For ADAM Technology In Delivery Of Zolmitriptan
7/17/2018 8:37:45 AM Zosano Says Positive Data From Evaluation Of Pharmacokinetics And Skin Tolerability Study For ADAM Technology
5/23/2018 8:36:40 AM Zosano Reports Publication Of Most Bothersome Symptom Data From ZOTRIP Pivotal Study In Headache